Rocket Pharmaceuticals Inc Stock News

Rocket Pharmaceuticals Inc (RCKT) shares closed 1.7% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 5.9% year-to-date, down 63.9% over the past 12 months, and up 193.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 54.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 271.5% The company's stock price performance over the past 12 months lags the peer average by 112.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Rocket Pharmaceuticals Inc (RCKT) shares closed today at 0.7% above its 52 week low of $20.39, giving the company a market cap of $1B. The stock is currently down 5.9% year-to-date, down 63.9% over the past 12 months, and up 202.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 41.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 271.5% The company's stock price performance over the past 12 months lags the peer average by 107.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)s stock price gapped up prior to trading on Monday . The stock had previously closed at $21.52, but opened at $22.34. Rocket Pharmaceuticals shares last traded at $21.98, with a volume of 699 shares changing hands. Several research analysts have commented on RCKT shares. Zacks Investment Research lowered Rocket Pharmaceuticals from [] The post Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up to $21.52 appeared first on ETF Daily News .

Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lifted by Chardan Capital from $56.00 to $60.00 in a research note published on Wednesday morning, Price Targets.com reports. The firm currently has a buy rating on the biotechnology companys stock. A number of other analysts have also issued reports on the company. Lifesci Capital restated an outperform []

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $20.92 and last traded at $21.14, with a volume of 2736 shares trading hands. The stock had previously closed at $23.11. A number of research firms recently issued reports on RCKT. SVB [] The post Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week Low at $20.92 appeared first on ETF Daily News .

Equities analysts expect Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) to report earnings per share of ($0.75) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Rocket Pharmaceuticals’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.81). Rocket Pharmaceuticals posted earnings of ($1.08) per share during the same quarter […]

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces positive clinical updates from its ongoing Phase 2 registrational trials for Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) and its ongoing Phase 1 trial for Pyruvate Kinase Deficiency (PKD) at the 63rd American Society of Hematology (ASH) Annual Meeting. The po

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President. Mr. Wilson brings nearly 20 years of legal, compliance and executive experience and accomplishment within the life sciences industry. Mr. Wilson will be responsible for the

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) hit a new 52-week low during trading on Monday . The company traded as low as $21.68 and last traded at $22.38, with a volume of 421 shares trading hands. The stock had previously closed at $22.79. Several research analysts have recently issued reports on the stock. William Blair restated a [] The post Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 52-Week Low at $21.68 appeared first on ETF Daily News .

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, will host an in-person Investor and Analyst Event in Atlanta that will simultaneously be webcast on Tuesday, Dec. 14, 2021, at 7:30 a.m. ET to discuss updates from three of the Companys lentiviral vector (LVV)-based gene therapy programs: RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I), RP-

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) hit a new 52-week low during trading on Tuesday . The stock traded as low as $23.15 and last traded at $23.59, with a volume of 424681 shares. The stock had previously closed at $23.67. Several research analysts have commented on RCKT shares. William Blair restated a buy rating on shares []